Recently, we have characterized the Ras association domain family 1A gene (RASSF1A) at the segment 3p21.3, which is frequently lost in variety of human cancers and epigenetically inactivated in many types of primary tumors, such as lung, breast, kidney, prostate and thyroid carcinomas. Here, we investigated the methylation status of the RASSF1A CpG island promoter in the pathogenesis of pancreatic cancer. RASSF1A hypermethylation was detected in 29 out of 45 (64%) primary adenocarcinomas, in 10 out of 12 (83%) endocrine tumors and in eight out of 18 (44%) pancreatitis samples. In seven out of eight pancreas cancer cell lines, RASSF1A was silenced and was retranscribed after treatment with 5-aza-2 0 -deoxycytidine. Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16
Introduction
Adenocarcinoma of the pancreas is one of the most aggressive human malignancies and is the fifth leading cause of cancer-related death (Greenlee et al., 2001) . In contrast to pancreatic adenocarcinoma, which derives from the exocrine pancreas, neuroendocrine tumors are rare (5%) and these tumors have an excellent prognosis. Pancreatic tumors are extremely difficult to diagnose at early stages since symptoms are unspecific and may be absent for a long time (Gunzburg and Salmons, 2001 ). As a result, patients with pancreatic adenocarcinoma have a poor prognosis with an overall 5-year survival rate of less than 5%. However, those patients with early adenocarcinomas have a substantially improved prognosis.
In the pancreas, a progression from normal ductal epithelium, to duct lesions, to invasive ductal adenocarcinoma has been proposed . This progression is associated with multiple genetic alterations including activating point mutations in the K-ras gene, the overexpression of HER-2/neu and the inactivation of the p16, p53, DPC4 and BRCA2 tumor suppressor genes (Hruban et al., 1998; Perugini et al., 1998) . About 80% of human pancreatic adenocarcinoma carries K-ras point mutations, which are almost exclusively located in codon 12 (Bos, 1989; Hruban et al., 1993) . About 30% of K-ras substitutions were detected in the pancreatic juice of patients with chronic pancreatitis, an inflammation, which is associated with increased risk to progress to cancer (Furuya et al., 1997) . K-ras mutations are frequently found in the pancreatic intraepithelial neoplasia (PanIN), a putative precursor lesion of pancreatic cancer (Tada et al., 1996; Laghi et al., 2002) . In neuroendocrine pancreatic tumors, K-ras mutations are rare (Sato et al., 2000) , whereas inactivation of the p16 tumor suppressor gene is a common event (Muscarella et al., 1998) . Allelic deletions (9p21) and epigenetic inactivation of p16 are frequently observed in adenocarcinomas (Caldas et al., 1994b; Schutte et al., 1997) .
Loss of heterozygosity (LOH) of several chromosomal regions (1p, 3p, 6p, 6q, 8p, 9p, 13q, 17p, 18q, 21q and 22q) have been reported in pancreatic carcinomas (Hahn et al., 1995) . LOH of 3p is a common event in the pathogenesis of pancreatic carcinoma, endocrine pancreatic tumors and other carcinomas (Hahn et al., 1995; Kok et al., 1997; Barghorn et al., 2001; Moore et al., 2001) . Recently, we and others have cloned and characterized the Ras association domain family 1 gene (RASSF1) from the tumor suppressor locus 3p21.3 (Dammann et al., 2000; Lerman & Minna, 2000; Burbee et al., 2001) . The two isoforms (RASSF1A and RASSF1C) are transcribed from different CpG island promoters. The RASSF1A promoter is frequently hypermethylated in a variety of primary human cancers, for example in lung, breast, kidney, thyroid and prostate carcinomas (Dammann et al., 2000; Agathanggelou et al., 2001; Burbee et al., 2001; Dammann et al., 2001a,b; Yoon et al., 2001; Liu et al., 2002; Schagdarsurengin et al., 2002) . Ectopic expression of RASSF1A in different cancer cell lines inhibited the tumorigenicity (Dammann et al., 2000; Burbee et al., 2001; Kuzmin et al., 2002) . Interestingly, loss of function mutations are uncommon and the main mechanism of RASSF1A inactivation is because of aberrant promoter methylation and allelic loss (Dammann et al., 2003) . The presence of a Ras association domain suggests that RASSF1A may be involved in the Ras signaling pathway. We and others have found that RASSF1 binds Ras, and its expression induces apoptosis (Vos et al., 2000; Khokhlatchev et al., 2002; Ortiz-Vega et al., 2002) . A recent report suggests, that RASSF1A blocks cell cycle progression by inhibiting cyclin D1 accumulation (Shivakumar et al., 2002) .
In this study, we investigated the aberrant CpG islands methylation of RASSF1A and p16
INK4a
in primary pancreatic adenocarcinomas, in neuroendocrine tumors of the pancreas, in pancreatitis and in pancreas cancer cell lines. Moreover, we analysed the mutations of codon 12 of K-ras to correlate RASSF1A inactivation and Ras activation.
Materials and methods

Tissues and cell lines
All 45 nonmicrodissected primary frozen pancreatic adenocarcinomas, 12 neuroendocrine pancreatic tumors (seven malignant and five benign), 18 chronic pancreatitis samples, five normal pancreatic tissues and pathological data were obtained from the tumor tissue bank of the Department of General, Visceral and Vascular Surgery of the University of Halle. Eight human pancreatic cancer cell lines: PA-TU-8988S (PATU-S), PA-TU-8988 T (PATU-T), PA-TU-8902 (PATU-2), MIA-PaCa-2 (PaCa-2), CAPAN1, CAPAN2, HUP-T3 and HUP-T4 were obtained from DSMZ or ATCC and cultured in the recommended growth medium. Pancreas cancer cell lines were treated with 5-aza-2 0 -deoxycytidine (5-Aza-CdR; Sigma). 2 Â 10 6 cells each were grown for 4 days in the presence of different concentrations of 5-Aza-CdR (0, 5 and 10 mm). RNA was isolated and RT-PCR was performed as described below. Genomic DNA was extracted from frozen tissues and cultured cells by a standard phenol/chloroform procedure and the total RNA was isolated by using of Trizol-Reagent (Gibco BRL, Life Technologies).
Bisulfite modification of the DNA and methylation-specific PCR (MSP) analysis Methylation of the RASSF1A promoter region was determined by bisulfite modification of genomic DNA (Clark et al., 1994; Dammann et al., 2000) . Promoter methylation was investigated by MSP as described by Herman et al. (1996) . The methylation status of the RASSF1A CpG islands in adenocarcinoma, cancer cell lines and pancreatitis was analysed as described by Schagdarsurengin et al. (2002) , and in neuroendocrine tumors and blood samples as described by Liu et al. (2002) . PCR products were analysed on a 2% Tris-borate EDTA agarose gel. To analyse the methylation status of the p16 gene, primers and conditions as described by Herman et al. (1996) were used.
RT-PCR analysis
Expression analysis was performed as described previously by Schagdarsurengin et al. (2002) . Briefly, 1 mg of RNA from pancreas cancer cell lines and HeLa was reverse transcribed with primer LHE4 in 25 ml of RT-Mix with AMV-RT (Promega GmBH, Heidelberg, Germany). A measure of 1 ml of cDNA was used for PCR amplification. The primers used for RASSF1A and RASSF1F: L27111 and U18275; and for RASSF1C: L27111 and U2g. PCR products were separated on 2% Tris-borate EDTA agarose gels and analysed by densitometry.
Analysis of K-ras by single-strand conformation polymorphism (SSCP)
To investigate mutations of exon 1 of the K-ras gene, we used the seminested PCR technique as described by Laghi et al. (2002) . Briefly, 100 ng genomic DNA were amplified in volume of 25 ml, containing 0.2 mm dNTPs, 1.5 mm MgCl 2 , 1% formamide, 10 pmol of each primer (FL, 5 0 -ccttatgtgtgacatgttctaatatagtcac; RL, 5 0 -cgtccacaaaatgattctgaattagctgtatc) and Taq polymerase (Invitek, Berlin, Germany) in the supplied buffer. PCR was performed at 941C for 30 s, at 601C for 30 s and at 721C for 30 s for 20 cycles. A 1 ml volume of the first round PCR product was transferred to 25 ml of fresh PCR mixture with primer RS (5 0 -aggcctgctgaaaatgac) and primer FL. The second PCR was performed at 921C for 30 s, at 571C for 30 s, at 721C for 30 s for 30 cycles. PCR products were precipitated with ethanol and dissolved in 2 ml H 2 O and 6 ml loading buffer containing 95% of formamide, denatured and separated on 15% polyacrylamide gel and stained with a silver procedure. SSCP pattern of blood DNA from healthy subjects was used as a control for wild-type (GGT) K-ras. Pattern of products amplified from PaCa-2, CAPAN1 and HUP-T3 were used to verify TGT, GTT and CGT mutation, respectively, as reported previously by Kita et al. (1999) and mutations were confirmed by direct sequencing.
Results
Epigenetic inactivation of the RASSF1A gene in pancreatic cancer
To elucidate the status of RASSF1A hypermethylation in pancreatic cancer, we treated genomic DNA of pancreatic carcinomas with sodium bisulfite and analysed the methylation status of RASSF1A promoter CpG island by MSP. First, we analysed the methylation status of the RASSF1A promoter of eight adenocarci-RASSF1A and K-ras in pancreatic carcinoma R Dammann et al noma cell lines (PATU-S, PATU-T, PATU-2, PaCa-2, CAPAN1, CAPAN2, HUP-T3 and HUP-T4) (Figure 1 ). Five cell lines (PATU-S, PATU-T, PATU-2, PaCa-2 and CAPAN2) were completely methylated, two cell lines (HUP-T3 and HUP-T4) were partially methylated and only CAPAN1 was unmethylated (Figure 1) . To correlate the methylation status with the RASSF1A transcription, we performed RT-PCR (Figure 2) . The RASSF1A and the alternative spliced RASSF1F transcript were detected in the partially methylated HUP-T4 and in HeLa, but not in PaCa-2, which was completely methylated (Figure 2 ). In the methylated PATU-S, PATU-T and PATU-2 cell lines, the RASSF1A transcript was missing, and in the unmethylated CAPAN1 and HUP-T3, RASSF1A was present (data not shown). We treated the pancreas carcinoma cell lines HUP-T4 and PaCa-2 with different concentrations of 5-AzadCR, a drug, which inhibits DNA methylation (Jones and Taylor, 1980) . After 4 days of treatment, we detected an increase of RASSF1A transcripts, indicating that promoter methylation was responsible for transcription silencing (Figure 2 ). The RASSF1C product, which was transcribed from an unmethylated downstream CpG island, was detected in all cancer cell lines (Figure 2) .
Then, we performed a detailed analysis of methylation status of the RASSF1A CpG island in different primary pancreatic specimens, including adenocarcinoma (AC), neuroendocrine tumor (NET) and pancreatitis tissue (PT) (Figure 1 and Table 1 ). In 29 out of 45 (64%) adenocarcinomas, RASSF1A was methylated and the lowest methylation frequency was detected in eight out of 18 (44%) pancreatitis cases. The highest rate of RASSF1A hypermethylation was detected in neuroendocrine tumors (83%), but was not detected in the corresponding blood samples. We analysed five nonmicrodissected normal pancreatic tissues from patients with adenocarcinoma and detected 80% of RASSF1A methylation. However, we found more methylation in the tumor than in the corresponding normal tissue (data not shown). In Table 1 , we summarize the methylation status of the RASSF1A gene depending on the grading, TNM staging or hormone production. RASSF1A inactivation was found in all tumor stages (T1-T4) and was higher in the poorly differentiated adenocarcinoma (75% of G3) compared to moderately differentiated (44% of G2) tumors. In neuroendocrine tumors, RASSF1A methylation was more common in tumors with metastasis (100% of M1) as in tumors without metastasis (71% of M0).
Methylation of p16
INK4a in pancreatic cancer
To correlate RASSF1A inactivation and aberrant methylation of p16, we examined the hypermethylation of the p16 CpG island in pancreatic carcinoma by MSP. Methylation of p16 was analysed in all the eight pancreas cancer cell lines. In three cell lines (PATU-S, PATU-T and PATU-2), the p16 CpG island was methylated and in three others (HUP-T3, HUPT4 and PaCa-2), it was unmethylated (data not shown). In the CAPAN1 and CAPAN2 cell lines, we could not obtain any products and most likely, p16 was deleted, since DNA amplification of RASSF1 indicated the presence of bisulfite-modified DNA (Figure 1) . Then, we investigated the methylation status of p16 in primary pancreatic AC, in NET and in pancreatitis tissue ( Figure 3 and Table 1 ). p16 was hypermethylated in 19 out of 44 (44%) adenocarcinomas, in two out of 12 (17%) endocrine tumors, in three out of 17 (18%) pancreatitis cases. In Table 1 , we summarize the methylation status of p16 depending on the grading and the pTNM classification. p16 inactivation was detected in all tumor stages and was more frequently methylated (P ¼ 0,064, w 2 test) in the poorly differentiated (70% of G3) compared to moderately differentiated adenocarcinoma (33% of G2). In endocrine tumors, p16 inactivation was more common in carcinomas with metastasis (40% of M1) than in the benign tumors (0% of M0). We found a tendency, that adenocarcinoma with RASSF1A methylation showed frequent p16 hypermethylation (14 of 28; 50%) com- . Methylationspecific (m) and unmethylation-specific (u) primers were used for MSP. The methylation-specific product and unmethylation-specific products were resolved on 2% TBE gels together with a 100 bp marker (100 bp). HeLa-DNA and in vitro methylated DNA (Methyl.) were used as controls for MSP RASSF1A and K-ras in pancreatic carcinoma R Dammann et al pared to tumors without RASSF1A methylation and p16 methylation (five of 16; 31%).
K-ras mutation of codon 12 in pancreatic cancer
The presence of a Ras association domain suggests that RASSF1A may be involved in the Ras signaling. To investigate the alteration of Ras in pancreatic cancer, we analysed exon 1 of K-ras by SSCP. All eight cancer cell lines had K-ras substitution of codon 12: PaCa-2 (TGT), (Figure 4 and data not shown). Then, we investigated the mutational status of codon 12 in pancreatic AC, in NET and in pancreatitis by SSCP (Figure 4 ). K-ras was mutated in 16 out of 45 (36%) of adenocarcinoma, but not in pancreatitis Figure 2 Re-expression of RASSF1 in pancreas cancer cell lines. Expression of RASSF1A in two pancreas cancer cell lines (HUP-T4, PaCa-2) and in unmethylated controls (HeLa) was analysed by RT-PCR. The cell lines were treated for 4 days with the indicated concentrations of 5-Aza-CdR. RASSF1A (347 bp), RASSF1F (240 bp), and RASSF1C (354 bp) were analysed by isoform-specific RT-PCR and resolved on 2% TBE gels together with a 100 bp marker. Expression of GAPD (170 bp) was determined as a control for RNA integrity in blood samples (B) . Methylation-specific (m) and the unmethylation-specific (u) products were resolved on 2% TBE gels together with a 100 bp marker (M) RASSF1A and K-ras in pancreatic carcinoma R Dammann et al (Table 2) . Seven GAT transitions, four GTT substitutions, four CGT transversions and a TGT mutation of codon 12 were detected in ACs. Furthermore, we detected no additional mutations of K-ras (codon 12 and 13) by direct sequencing and we found no mutation in the normal pancreatic tissues. In an endocrine tumor, which was methylated for RASS-F1A, a GCT mutation was observed. In Table 2 , we summarize the K-ras mutational status associated with RASSF1A methylation or p16 inactivation. Interestingly, K-ras mutation was observed significantly more frequent in the RASSF1A unmethylated AC (11 out of 16 ¼ 69%) compared to the RASSF1A methylated samples (five out of 29 ¼ 17%) (P ¼ 0.001, w 2 ; 95% conf. 0.023-0.396). However, this correlation was not found between K-ras substitutions and p16 methylation (Table 2) .
HUP-T4 (GTT/WT), HUP-T3, (CGT/WT), CAPAN2 (TGT), CAPAN1 (GTT), PATU-2 (GTT/WT), PATU-T (GTT) and PATU-S (GTT)
Discussion
We and others have reported frequent hypermethylation of RASSF1A in human carcinomas (Dammann et al., 2003) . Here, we investigated the role of RASSF1A inactivation in pancreatic cancer and demonstrated that aberrant RASSF1A methylation is a frequent event (64%) in AC. The highest methylation was found in the rare NETs (83%) and in pancreas cancer cell lines (88%). A recent study has shown that methylation of several other cancer-related CpG islands occurred less frequent in endocrine tumors (Chan et al., 2003) . Methylation of RASSF1A is generally rare in normal, non-neoplastic tissues , and was not detected in the blood samples. However, we detected frequent RASSF1A and p16 methylation in the normal counterparts of RASSF1A methylated adenocarcinoma. This might be because of the presence of PanIN in the nonmicrodissected specimens or attributable to tumor cell infiltration into the normal tissue, which was reported for prostate cancer . Interestingly, in the malignant endocrine carcinoma with metastasis (M1), silencing of RASSF1A and p16 was more common than in benign endocrine tumors (M0). In contrast, a trend for more frequent RASSF1A methylation was noted in the metastasis-free AC (N0 and M0). In the T1-T4 staging, no significant changes in RASSF1A and p16 inactivation rates were observed. In AC, aberrant p16 methylation was 2.4 times higher than in pancreatitis. Furthermore, p16 was more than twice as much inactivated in the poorly differentiated G3 (70%) compared to the moderately differentiated G2 AC (33%). A similar trend was observed for RASSF1A hypermethylation (G2 ¼ 44% versus G3 ¼ 75%). However, in chronic pancreatitis tissue, which was apparently free of malignancy, the same methylation frequency of RASSF1A was detected (44%). It will be interesting to determine whether this inactivation occurs as a part of the aging process or inflammation of the pancreas, two events, which were associated with methylation of p16 and other genes in normal colon mucosa and ulcerative colitis (Ahuja et al., 1998; Hsieh et al., 1998; Issa et al., 2001) . Consistent with our data, a similar methylation frequency of the p16 gene was reported in 39% of ACs, in 2-21% of precursor lesions PanIN and in 9% of NETs (Schutte et al., 1997; Fukushima et al., 2002; Chan et al., 2003) . In thyroid cancer, we reported that RASSF1A inactivation and p16 methylation was higher in more aggressive tumors compared to less malignant forms (Schagdarsurengin et al., 2002) , and we observed a similar trend for RASSF1A inactivation in prostate cancer . In nonsmall cell lung carcinoma, RASSF1A methylation is associated with impaired patient survival (Burbee et al., 2001; Tomizawa et al., 2002) . However, here we detected the highest incidence of RASSF1A methylation in the neuroendocrine pancreatic tumors, which are associated with a much better prognosis than the ACs.
The role of RASSF1A as a negative Ras effector in a proapoptotic signaling pathway suggests that alteration of both genes may be linked to each other. Here, we observed that RASSF1A inactivation and K-ras activation are mutually exclusive events in pancreatic AC (P ¼ 0.001). A similar correlation between aberrant RASSF1A methylation and K-ras wild-type status was Figure 4 SSCP screening of K-ras mutations in pancreatic carcinoma. SSCP pattern of blood DNA (B) from a healthy subject was used as a control for wild-type (GGT) codon 12 of Kras. PCR products of CAPAN2, CAPAN1 and HUP-T4 cell lines were used to verify homozygote TGT, homozygote GTT and heterozygote GTT þ GGT (G T / G T) substitutions of K-RAS, respectively, and compared to the pattern of different primary adenocarcinoma (AC). PCR products were separated on 15% polyacrylamide gel together with a 100 bp DNA ladder (M) and stained with silver Table 2 RASSF1A methylation, p16 methylation and K-ras mutation (codon 12) in primary pancreatic AC Case K-ras mutation
RASSF1A and K-ras in pancreatic carcinoma R Dammann et al reported in colorectal cancer (van Engeland et al., 2002) and in stage I lung adenocarcinoma (Tomizawa et al., 2002) . In contrast to pancreatic adenocarcinoma, K-ras substitutions in neuroendocrine pancreatic tumors are rare (Sato et al., 2000) , and we detected in these tumors only a single K-ras mutation and intensive RASSF1A inactivation (83%). Likewise, high frequency of RASS-F1A methylation was observed in 79% of small cell lung carcinoma (Dammann et al., 2001a) and in 84% of nasopharyngeal cancer (Kwong et al., 2002) , and in these carcinomas, Ras mutations are as well uncommon (Bos, 1989) . These observations may indicate that the occurrence of frequent RASSF1A inactivation may exclude the necessity of K-ras activation to alter Ras signaling in carcinogenesis. Activating mutations in codon 12 (from GGT to GAT, or to GTT, and, more rarely, to CGT, or to TGT) of the K-ras gene are the most common genetic alterations in pancreatic ACs. In this study, we detected several GAT, GTT, CGT and a TGT mutation of K-ras, but the incidence of K-ras activation (36%) was lower than expected from literature. However, this lower frequency cannot be attributed to technical limitation, since the SSCP assay used in this study is able to detect one mutated allele among 120 000 and 60 000 normal alleles for the GAT and GTT mutations, respectively, and therefore, is more sensitive than MSP (Herman et al., 1996; Laghi et al., 2002) . In some studies, low mutation rates of K-ras were reported for pancreatic cancer, for example, in intraductal papillary neoplasms and in medullary carcinomas, K-ras mutations were detected in 60 and 31% of cases, respectively (Tada et al., 1991; Wilentz et al., 2000) . In AC with high frequencies of microsatellite instability, K-ras mutations were detected only in 23% of the pancreatic carcinomas (Yamamoto et al., 2001 ). It will be interesting to determine, whether the low rate of mutations in our study is a result of these forms of AC and/or of different carcinogenesis in distinct geographic regions as reported in a study from Taiwan (Chang et al., 2001) . The high frequency of K-ras mutations and RASSF1A methylation in the cell lines could be attributed to additional genetic and epigenetic changes, which occurred in the propagation of these cell lines, for instance excessive CpG island hypermethylation was often observed in cancer cell lines (Smiraglia et al., 2001) .
In summary, we describe a distinct pattern of both genetic and epigenetic changes in pancreatic ACs and pancreatic NETs. The observation that RASSF1A inactivation and K-ras activation are mutually exclusive events in the development of certain carcinomas could further pinpoint the function of RASSF1A as a negative effector of Ras in an alternative, proapoptotic signaling pathway (Vos et al., 2000; Khokhlatchev et al., 2002) . It will be interesting to analyse the association of K-ras mutations and RASSF1A inactivation in PanIN, which might indicate high-risk precursors of chronic pancreatitis that might progress to cancer. Further studies are necessary to determine, whether RASSF1A inactivation is part of the inflammation or aging process of the pancreas and is associated with increased risk to develop cancer.
Abbreviations RASSF1, Ras association domain family 1 gene; PanIN, pancreatic intraepithelial neoplasia; LOH, loss of heterozygosity; 5-Aza-CdR, 5-aza-2 0 -deoxycytidine; MSP, methylationspecific PCR; TNM, tumor-node-metastasis; SSCP, singlestrand conformation polymorphism; WT, wild type.
